LGD-4033 - Selective Androgen Receptor Modulator (SARM)

LGD-4033 (Ligandrol, VK5211)

Illegal Distribution via Internet

In the following publication in 2015, the identification of a SARM-based substance distributed via Internet-based suppliers as LGD4033 is reported:

Mario Thevis, Andreas Lagojda, Dirk Kuehne, Andreas Thomas, Josef Dib, Annelie Hansson, Mikael Hedeland, Ulf Bondesson, Tina Wigger, Uwe Karst and Wilhelm Schänzer: Characterization of a non-approved selective androgen receptor modulator drug candidate sold via the Internet and identification of in vitro generated phase-I metabolites for human sports drug testing. Rapid Commun. Mass Spectrom. 2015, 29, 991–999.
Abstract

Similar articles followed, for example in 2017:
Van Wagoner RM, Eichner A, Bhasin S, Deuster PA, Eichner D. Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet. JAMA. 2017 Nov 28;318(20):2004-2010. 
Abstract and free article

Physiology

"Background. Concerns about potential adverse effects of testosterone on prostate have motivated the development of selective androgen receptor modulators that display tissue-selective activation of androgenic signaling. LGD-4033, a novel nonsteroidal, oral selective androgen receptor modulator, binds androgen receptor with high affi nity and selectivity."

Basaria S, Collins L, Dillon EL, et al. The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men. J Gerontol A Biol Sci Med Sci. 2013;68(1):87-95.
Abstract and free article

Doping

The first two positive doping control samples proofing the abuse of LGD-4033 were reported by the World Anti-Doping Agency (WADA) in 2015.
see also WADA statistics for SARMs SARMs